Our study demonstrates that AML with t(8;21)/RUNX1–RUNX1T1 is arrested at specific stages of myeloid differentiation, which significantly correlates with genetic lesions, clinical presentation, chemosensitivity, treatment response and overall outcomes. Here, RUNX1 is linked to acute myeloid leukemia.